Dicerna Pharmaceuticals Inc (DRNA) Stake Maintained by Ra Capital Management, LLC
Ra Capital Management, LLC
recently disclosed that they own 8.6% of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in a Schedule 13D/A disclosure that was filed with the SEC on Friday, January 19th. The investor owns 4,462,313 shares of the stock worth about $39,402,224. The reporting parties listed on the disclosure included RA Capital Management, LLC, Peter Kolchinsky and RA Capital Healthcare Fund, LP. The disclosure is available through EDGAR at this hyperlink.
DRNA has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Evercore ISI initiated coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $14.00 price objective for the company. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $8.25.
Dicerna Pharmaceuticals Inc (NASDAQ DRNA) traded down $0.14 during mid-day trading on Friday, reaching $8.83. 162,162 shares of the company’s stock were exchanged, compared to its average volume of 335,321. The firm has a market cap of $456.00, a P/E ratio of -2.57 and a beta of 2.84. Dicerna Pharmaceuticals Inc has a 12 month low of $2.42 and a 12 month high of $10.24.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.22). The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company’s revenue was up 192.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.68) EPS. analysts predict that Dicerna Pharmaceuticals Inc will post -2.93 EPS for the current year.
In other news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was acquired at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 29.41% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dicerna-pharmaceuticals-inc-drna-stake-maintained-by-ra-capital-management-llc/1814587.html.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.